Results 91 to 100 of about 180 (117)
Some of the next articles are maybe not open access.
CNS Drugs, 2011
Cladribine, an immunosuppressant that selectively reduces peripheral lymphocyte levels, has potential as an oral therapy for relapsing-remitting multiple sclerosis. An oral (tablet) formulation is being investigated in clinical trials. In the large, well designed, phase III CLARITY trial, short-course treatment with oral cladribine (cumulative dose of ...
Victoria J, Muir, Greg L, Plosker
openaire +2 more sources
Cladribine, an immunosuppressant that selectively reduces peripheral lymphocyte levels, has potential as an oral therapy for relapsing-remitting multiple sclerosis. An oral (tablet) formulation is being investigated in clinical trials. In the large, well designed, phase III CLARITY trial, short-course treatment with oral cladribine (cumulative dose of ...
Victoria J, Muir, Greg L, Plosker
openaire +2 more sources
Cladribine tablets for the treatment of relapsing–remitting multiple sclerosis
Expert Opinion on Pharmacotherapy, 2012Multiple sclerosis (MS) is a chronic immune-mediated disorder of the central nervous system leading to progressive neurodegeneration and disability. Until 2010, all approved disease-modifying drugs for MS required parenteral administration, which is associated with suboptimal adherence.
COMI , GIANCARLO +4 more
openaire +2 more sources
Multiple Sclerosis and Related Disorders, 2023 Cladribine tablets are a highly effective immune reconstitution therapy licensed for treating relapsing multiple sclerosis (RMS) in Europe since 2017. Currently, there is a high demand for real-world data from different clinical settings on the effectiveness and safety profile of cladribine in MS.Within this report, we retrospectively evaluated the ...
V Popescu +2 more
exaly +5 more sources
Cladribine Tabletsʼ Potential in Multiple Sclerosis Treatment
Journal of Neuroscience Nursing, 2008Multiple sclerosis (MS) is an inflammatory and neurodegenerative disease of the central nervous system occurring in genetically susceptible individuals. T and B lymphocytes are thought to be important in the pathogenesis of MS. Among the unmet needs in MS therapeutics are agents with improved efficacy and safety profiles and improved routes of ...
Kathleen, Costello, Jack C, Sipe
openaire +2 more sources
[Recommendations for the use of cladribine tablets in recurring multiple sclerosis].
Revista de neurologia, 2020Cladribine is a prodrug, a synthetic analogue of deoxyadenosine, approved for use as selective immune reconstitution therapy in very active recurring multiple sclerosis in adults.To review the development of the drug, its mechanism of action and the efficacy and safety data obtained to date, as well as to establish recommendations of Spanish experts ...
C, Oreja-Guevara +7 more
openaire +1 more source
Real-world Experience with Cladribine Tablets in the MSBase Registry (2942)
Neurology, 2021Butzkueven, Helmut +21 more
openaire +2 more sources
Pregnancy of MS patients treated with cladribine tablets (1477)
Neurology, 2020Kerstin Hellwig +5 more
openaire +1 more source